Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Labopin

Showing results (251-260 of 443) with videos related to

Pageof 45
Sort By:
Oncotarget|January 20, 2018
Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMTGabrielle Roth-Guepin, Jonathan Canaani, Annalisa Ruggeri, et al.
Bone Marrow Transplantation|November 5, 2025
Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haplo-identical transplants with post transplant cyclophosphamide, a study from of the CTIWP-EBMTVanderson Rocha, Myriam Labopin, Anna Maria Raiola, et al.
Blood|December 15, 2011
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantationChristoph Schmid, Myriam Labopin, Arnon Nagler, et al.
American Journal of Hematology|November 18, 2024
The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13)Ann-Kristin Schmälter, Myriam Labopin, Jurjen Versluis, et al.
Bone Marrow Transplantation|May 13, 2022
Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMTIvetta Danylesko, Christophe Peczynski, Myriam Labopin, et al.
Transplantation and Cellular Therapy|July 28, 2024
Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMTSebastian Giebel, Myriam Labopin, Zinaida Peric, et al.
The Oncologist|February 13, 2016
Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMTSebastian Giebel, Myriam Labopin, Adalberto Ibatici, et al.
Transfusion|June 2, 2016
Impact of cord blood banking technologies on clinical outcome: a Eurocord/Cord Blood Committee (CTIWP), European Society for Blood and Marrow Transplantation and NetCord retrospective analysisRiccardo Saccardi, Luciana Tucunduva, Annalisa Ruggeri, et al.
Bone Marrow Transplantation|January 14, 2018
Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow TransplantationRaynier Devillier, Myriam Labopin, Patrice Chevallier, et al.
Bone Marrow Transplantation|March 6, 2026
Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working PartyGesine Bug, Myriam Labopin, Jennifer L Byrne, et al.
Pageof 45

Showing results (251-260 of 443) with videos related to

Sort By:
Pageof 45
Oncotarget|January 20, 2018
Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMTGabrielle Roth-Guepin, Jonathan Canaani, Annalisa Ruggeri, et al.
Bone Marrow Transplantation|November 5, 2025
Use of bone marrow cells is associated with improved outcomes when compared to peripheral blood stem cell after haplo-identical transplants with post transplant cyclophosphamide, a study from of the CTIWP-EBMTVanderson Rocha, Myriam Labopin, Anna Maria Raiola, et al.
Blood|December 15, 2011
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantationChristoph Schmid, Myriam Labopin, Arnon Nagler, et al.
American Journal of Hematology|November 18, 2024
The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13)Ann-Kristin Schmälter, Myriam Labopin, Jurjen Versluis, et al.
Bone Marrow Transplantation|May 13, 2022
Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMTIvetta Danylesko, Christophe Peczynski, Myriam Labopin, et al.
Transplantation and Cellular Therapy|July 28, 2024
Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMTSebastian Giebel, Myriam Labopin, Zinaida Peric, et al.
The Oncologist|February 13, 2016
Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMTSebastian Giebel, Myriam Labopin, Adalberto Ibatici, et al.
Transfusion|June 2, 2016
Impact of cord blood banking technologies on clinical outcome: a Eurocord/Cord Blood Committee (CTIWP), European Society for Blood and Marrow Transplantation and NetCord retrospective analysisRiccardo Saccardi, Luciana Tucunduva, Annalisa Ruggeri, et al.
Bone Marrow Transplantation|January 14, 2018
Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow TransplantationRaynier Devillier, Myriam Labopin, Patrice Chevallier, et al.
Bone Marrow Transplantation|March 6, 2026
Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working PartyGesine Bug, Myriam Labopin, Jennifer L Byrne, et al.
Pageof 45